Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28904089 | 0.98 | KDM4E (0.53) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL475746 | 0.92 | CA1 (0.61) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL39734 | 0.89 | CA1 (0.60) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL7234945 | 0.89 | CA12 (0.60) | KDM4EALDH1A1CA1CA2CA12 | |
| SCHEMBL9121827 | 0.89 | CA12 (0.60) | KDM4EALDH1A1CA1CA2CA12 | |
| Methyl Alcohol SCHEMBL28269742 | 0.87 | CA12 (0.58) | KDM4EALDH1A1CA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL3361588 | 0.87 | CA1 (0.58) | KDM4EALDH1A1CA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL19118500 | 0.87 | CA1 (0.58) | KDM4EALDH1A1CA1CA2CA12 | |
| Methyl 3,5-Dimethoxybenzoate SCHEMBL204865 | 0.87 | CA1 (0.61) | KDM4EALDH1A1CA1CA2CA12 | |
| 3,5-Dimethoxybenzoic Acid SCHEMBL503889 | 0.85 | RXRA (0.64) | KDM4EALDH1A1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024199063-A1 | PHOSPHORUS OR SULFUR-CONTAINING MACROCYCLE AND USE THEREOF | 浙江养生堂天然药物研究所有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-115368239-B | Synthesis and pharmaceutical application of cinnamate derivative | 南开大学 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024024490-A1 | COMPOSITION FOR FORMING RESIST UNDERLAYER FILM | 日産化学株式会社 | 2024-02-01 | — | — | WO | disclosed |
| WO-2023238920-A1 | COMPOSITION FOR FORMING RESIST UNDERLAYER FILM TO REDUCE ENVIRONMENTAL IMPACT | 日産化学株式会社 | 2023-12-14 | — | — | WO | disclosed |
| WO-2023181960-A1 | COMPOSITION FOR FORMING PROTECTIVE FILM | 日産化学株式会社 | 2023-09-28 | — | — | WO | disclosed |
| CN-115368239-A | Synthesis of cinnamate derivative and pharmaceutical application thereof | 南开大学 | 2022-11-22 | — | — | CN | disclosed |
| CN-109627266-B | Binuclear cobalt antibacterial material and preparation method thereof | 河南工程学院 | 2020-12-25 | — | — | CN | disclosed |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2013-04-25 | — | — | US | disclosed |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2013-04-25 | — | — | US | disclosed |
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| CN-1649865-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMA INC (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20040106607-A1 | New compounds | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004014902-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-1992004315-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059840-A1 | SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, GSAP | KDM4E 2445/4885ALDH1A1 3031/4885CA1 353/4885 |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | KDM4E 3972/4885ALDH1A1 3466/4885CA1 972/4885 |
| US-20040106607-A1 | New compounds | MTX1, MLX, TPX2 | KDM4E 2826/4885ALDH1A1 1359/4885CA1 3796/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | KDM4E 3972/4885ALDH1A1 3466/4885CA1 972/4885 |
| US-20130102593-A1 | PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | KDM4E 1906/4885ALDH1A1 2955/4885CA1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.